Using nanoparticles to prevent the progression of osteoarthritis after joint injuries.
Tissue Adhesive RNA Interference Nanoparticles to Block Progression of Posttraumatic and Spontaneous Osteoarthritis.
This study is testing a new injection treatment for people with osteoarthritis that uses tiny particles to help protect cartilage in the joints, aiming to reduce pain and improve everyday life without needing surgery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-10886730 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment approach for osteoarthritis (OA) and post-traumatic osteoarthritis (PTOA) by using tissue adhesive RNA interference nanoparticles. These nanoparticles aim to block the activity of specific enzymes that degrade cartilage, which is crucial for preventing further joint damage and pain. The treatment will be administered through injections directly into the affected joint, targeting the source of the problem rather than just alleviating symptoms. By addressing the underlying causes of OA and PTOA, this research seeks to improve patients' quality of life and reduce the need for joint replacement surgeries.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced joint injuries, particularly younger patients at risk for developing post-traumatic osteoarthritis.
Not a fit: Patients with advanced osteoarthritis requiring joint replacement or those without a history of joint injuries may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a disease-modifying treatment that halts the progression of osteoarthritis and improves joint health.
How similar studies have performed: While previous attempts to block cartilage-degrading enzymes have failed, this approach using targeted nanoparticles represents a novel strategy that has not been extensively tested.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Duvall, Craig Lewis — Vanderbilt University
- Study coordinator: Duvall, Craig Lewis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.